[go: up one dir, main page]

MX2009009701A - Agente preventivo y/o terapeutico novedoso para neuropatia diabetica. - Google Patents

Agente preventivo y/o terapeutico novedoso para neuropatia diabetica.

Info

Publication number
MX2009009701A
MX2009009701A MX2009009701A MX2009009701A MX2009009701A MX 2009009701 A MX2009009701 A MX 2009009701A MX 2009009701 A MX2009009701 A MX 2009009701A MX 2009009701 A MX2009009701 A MX 2009009701A MX 2009009701 A MX2009009701 A MX 2009009701A
Authority
MX
Mexico
Prior art keywords
diabetic
therapeutic agent
prophylactic
nerve disorder
abnormal
Prior art date
Application number
MX2009009701A
Other languages
English (en)
Inventor
Toshiaki Aoki
Nobuhito Murai
Seiji Tamura
Hiroko Yamamoto
Nozomu Hamakawa
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2009009701A publication Critical patent/MX2009009701A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describe un agente profiláctico y/o terapéutico excelente para neuropatía diabética, el cual comprende 2- [(indeno-7-iloxi substituido)metil]morfolina representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo como un ingrediente activo. El agente profiláctico y/o terapéutico es particularmente útil como un agente profiláctico y/o terapéutico para trastorno de nervio motor diabético (por ejemplo, disminución en fuerza muscular (disminución en fuerza muscular hasta un grado de ser incapaz de caminar independientemente)), trastorno de nervio sensorial diabético (parestesia (sensación de vibración anormal), alodinia, sensación reducida (entumecimiento de extremidades, psicroestesia) o dolor), o trastorno de nervio autónomo diabético (por ejemplo, habituación anormal del intestino, tal como constipación y diarrea, disfunción urinaria, impotencia, hipotensión ortoestática, dishidrosis, variabilidad anormal en frecuencia cardíaca, vaciamiento gástrico retardado). También se describe un agente de disminución de una condición de enfermedad de un trastorno de nervio diabético.
MX2009009701A 2007-03-15 2008-03-14 Agente preventivo y/o terapeutico novedoso para neuropatia diabetica. MX2009009701A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007066727 2007-03-15
JP2007242210 2007-09-19
PCT/JP2008/054710 WO2008111669A1 (ja) 2007-03-15 2008-03-14 糖尿病性神経障害の新規予防剤及び／又は治療剤

Publications (1)

Publication Number Publication Date
MX2009009701A true MX2009009701A (es) 2009-10-07

Family

ID=39759597

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009701A MX2009009701A (es) 2007-03-15 2008-03-14 Agente preventivo y/o terapeutico novedoso para neuropatia diabetica.

Country Status (12)

Country Link
US (2) US20100113451A1 (es)
EP (1) EP2123643A4 (es)
JP (1) JP5278308B2 (es)
KR (1) KR20090130052A (es)
AU (1) AU2008225379A1 (es)
BR (1) BRPI0808806A2 (es)
CA (1) CA2680938A1 (es)
IL (1) IL200669A0 (es)
MX (1) MX2009009701A (es)
RU (1) RU2465906C2 (es)
TW (1) TW200846003A (es)
WO (1) WO2008111669A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2428181C1 (ru) * 2010-05-25 2011-09-10 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. И.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Способ снижения уровня гликемии и инсулинорезистентности у больных сахарным диабетом 2 типа

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149386A (zh) * 2008-09-11 2011-08-10 安斯泰来制药株式会社 伤害感受性疼痛的新型治疗用药物组合物
JPWO2010029959A1 (ja) * 2008-09-11 2012-02-02 アステラス製薬株式会社 モルホリン誘導体の新規な塩

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109088A (en) * 1975-01-29 1978-08-22 Yamanouchi Pharmaceutical Co., Ltd. 2-(indenyloxymethyl) morpholine derivatives
JPS52111580A (en) * 1976-03-15 1977-09-19 Yamanouchi Pharmaceut Co Ltd Novel indene derivatives and salts thereof
WO1994018182A1 (fr) * 1993-02-10 1994-08-18 Yamanouchi Pharmaceutical Co., Ltd. Derive de morpholine
WO2000015223A1 (en) * 1998-09-15 2000-03-23 Eli Lilly And Company Treatment of persistent pain
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
WO2006006617A1 (ja) * 2004-07-14 2006-01-19 Astellas Pharma Inc. 中枢神経疾患発症後の機能障害の回復促進剤
US7919510B2 (en) * 2005-05-18 2011-04-05 Neuraxon, Inc Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity
ATE530175T1 (de) * 2006-06-08 2011-11-15 Ucb Pharma Gmbh Therapeutische kombination für schmerzhafte medizinische zustände

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2428181C1 (ru) * 2010-05-25 2011-09-10 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. И.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Способ снижения уровня гликемии и инсулинорезистентности у больных сахарным диабетом 2 типа

Also Published As

Publication number Publication date
IL200669A0 (en) 2010-05-17
KR20090130052A (ko) 2009-12-17
RU2465906C2 (ru) 2012-11-10
EP2123643A4 (en) 2011-12-07
JPWO2008111669A1 (ja) 2010-06-24
RU2009138032A (ru) 2011-04-20
US20130023535A1 (en) 2013-01-24
US20100113451A1 (en) 2010-05-06
CA2680938A1 (en) 2008-09-18
TW200846003A (en) 2008-12-01
JP5278308B2 (ja) 2013-09-04
AU2008225379A1 (en) 2008-09-18
EP2123643A1 (en) 2009-11-25
BRPI0808806A2 (pt) 2014-08-19
WO2008111669A1 (ja) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2012005500A3 (ko) 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
NZ589445A (en) Rasagiline for parkinson's disease modification
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP4378482A3 (en) Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
SG153830A1 (en) Galenic formulations of organic compounds
FR12C0052I1 (es)
WO2014146082A1 (en) Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
MX342007B (es) Composicion de farmaco conjugado.
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2006124447A3 (en) Substituted n-arylpyrrolidines as selective androgen receptor modulators
WO2005056524A3 (en) Therapeutic agents useful for treating pain
MX2008013827A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
HRP20140280T1 (hr) Uporaba 1-fenil-3-dimetilamino-propan spojeva u terapiji neuropatske boli
WO2004087048A3 (en) Benzamide modulators of metabotropic glutamate receptors
MX2009009701A (es) Agente preventivo y/o terapeutico novedoso para neuropatia diabetica.
WO2008060332A3 (en) Methods for treating or reducing muscle fatigue
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
MX347237B (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
CA2262268C (en) Method of treating impotence due to spinal cord injury
NZ595798A (en) Ectoparasiticidal methods and formulations
WO2010022326A3 (en) Transdermal delivery of apomorphine using microneedles
EA200801310A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
WO2007139433A8 (en) Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application
RU2009145804A (ru) Аксомадол для лечения боли от артроза

Legal Events

Date Code Title Description
FA Abandonment or withdrawal